The unusual move at FDA comes shortly after the agency's longtime vaccine chief was forced out over disagreements with Makary ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

Novavax's recent performance shows improvement, but significant challenges persist, impacting long-term growth and stability. The company's financials have strengthened due to strategic moves ...

GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings ...

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (NYSE:TAK). The terms of the amended agreement for the development, ...

Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax WASHINGTON -- The Trump administration's effort to impose new ...